Illumina (ILMN) Stock Analysis & Winston Score

Illumina makes machines and chemicals that read DNA — a process called genetic sequencing. Its main products are sequencing instruments and the consumable reagents (chemical kits) that labs must buy repeatedly to run tests. Customers include hospitals, university research labs, pharmaceutical companies, and government health agencies around the world. Illumina is the dominant global leader in DNA sequencing equipment, controlling the large majority of the market. The company earns money two ways: selling the sequencing machines upfront and then selling the consumables and software that customers need to keep using them. This "razor and blades" model creates steady, recurring revenue. Illumina operates globally, with significant sales in the US, Europe, and Asia, and generated roughly $4 billion in annual revenue in recent fiscal periods. Its deep installed base of instruments and proprietary chemistry create a strong competitive moat, but the key risk is growing competition from newer sequencing technologies, particularly from companies like Pacific Biosciences and Oxford Nanopore.